连花清瘟胶囊治疗流行性感冒的有效性及安全性的系统评价

Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review

系统评价连花清瘟胶囊治疗流行性感冒的有效性及安全性。计算机检索中国知网(CNKI),万方数字化期刊全文数据库(WANFANG DATA),维普中文期刊数据库(VIP),Pub Med以及the Cochrane library,检索时限均为建库至2017年2月。收集连花清瘟胶囊治疗流感的随机对照试验,2位研究者独立进行文献筛选和资料提取工作并进行交叉核对,如遇分歧讨论解决。运用Revman5.3进行Meta分析。共纳入10个研究,计1 525例患者。Meta分析结果显示:与奥司他韦相比,连花清瘟胶囊在缓解流感症状方面疗效优于奥司他韦,其中头痛消失时间[SMD=-0.25,95%CI为(-0.48,-0.01)]、咽痛消失时间[SMD=-0.53,95%CI(-0.72,-0.34)]、咳嗽消失时间[SMD=-0.39,95%CI(-0.57,-0.21)]、周身酸痛消失时间[SMD=-0.49,95%CI(-0.78,-0.21)]、乏力消失时间[SMD=-0.56,95%CI(-0.82,-0.29)]、退热时间[SMD=-3.47,95%CI(-6.27,-0.67)]。除鼻塞和病毒核酸转阴时间外,2组差异均具有统计学意义。与利巴韦林相比,在临床疗效方面,连花清瘟胶囊优于利巴韦林[RR=1.53,95%CI(1.24,1.90)],2组差异具有统计学意义。与氨咖黄敏胶囊比较,连花清瘟胶囊体温疗效优于对照组[RR=1.37,95%CI(1.19,1.57)]。相比较奥司他韦、利巴韦林、氨咖黄敏胶囊,连花清瘟胶囊治疗流行性感冒具有一定的疗效,且安全性较高;但由于临床研究质量不高,上述结论有待高质量临床试验进一步验证。

To evaluate the efficacy and safety of Lianhua Qingwen capsule for influenza.All reports of the randomized controlled trials （RCTs） on Lianhua Qingwen capsule treating influenza were retrieved from database of CNKI, WANFANG DATA, VIP, PubMed, the Cochrane Library by February 2017.The studies were screened according to the inclusion and exclusion criteria, the data were extracted by 2 authors, the quality of the included RCTs was assessed, and meta-analysis was performed using Revman5.3 software.A total of 1 525 patients and 10 studies were included.The results of meta analysis showed that compared with oseltamivir, Lianhua Qingwen capsule was more effective in alleviating flu symptoms, including the time of headaches disappeared [SMD=-0.25,95% CI（-0.48,-0.01）], the time of sore throat disappeared [SMD=-0.53,95% CI（-0.72,-0.34）], the time of cough disappeared [SMD=-0.39,95%CI（-0.57,-0.21）], whole body aches disappeared [SMD=-0.49, 95% CI （-0.78,-0.21）], the time of weak disappeared [SMD=-0.56,95%CI （-0.82,-0.29）], and the time of abatement of fever [SMD=-3.47,95%CI（-6.27,-0.67）].Also, there were some statistical significant differences between the two groups except nasal congestion and the time of virus turning negative.Compared with Ribavirin, Lianhua Qingwen capsule was more effective in terms of the rate of temperature effect, [RR=1.53, 95% CI （1.24, 1.90）], the difference between the two groups was statistically significant.Compared with Ankahuangmin capsules, significant differences were found in terms of the he rate temperature effect [RR=1.37, 95%CI （1.19,1.57）].Current evidence shows that Lianhua Qingwen capsule is more effective and safer than Oseltamivir, Ribavirin and Ankahuangmin capsules.Due to the low quality of the clinical research, the accuracy of this conclusion needs to be conducted to verify.